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Abstract 
The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted 
agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine 
kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of 
many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it 
is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly 
evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting 
undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these 
undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize 
adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated 
adverse events. 
 
 
 
 
  
Introduction 
Tyrosine kinase inhibitors (TKI) are a novel type of drug, designed to target signaling pathways 
deregulated in cancer by blocking the ATP-binding pocket of specific receptor tyrosine kinases (RTK). 
TKIs compete with ATP for binding to the intracellular domain of wild-type and/or mutant forms of 
RTKs and, consequently, inhibit signal transduction. 
 
Although TKIs are designed to target specific RTKs, it is increasingly apparent that many TKIs may 
display unexpected effects on other kinases and may trigger the appearance of undesirable side effects. 
The observed incidence of side effects associated with TKIs varies between clinical studies, depending on 
treatment schedule, dosage, patient characteristics, predisposing factors, secondary diseases, and 
concurrent administration of other drugs. Moreover, these agents, which do not specifically target tumor 
cells, are able to act on normal cells, eliciting diverse side effects. 
 
Sunitinib (sunitinib malate; Sutent; Pfizer Inc.) is a targeted TKI able to inhibit members of the RTK 
families containing a split-kinase domain (Fig. 1; ref. 1). These families include VEGF receptor (VEGFR) 
types 1 (FLT1), 2 (KDR), and 3 (FLT4); platelet-derived growth factor receptors A and B (PDGFRA and 
PDGFRB); the stem cell factor receptor (cKIT); FMS-like tyrosine kinase 3 (FLT3); colony-stimulating 
factor 1 receptor (CSF-1R); and glial cell line–derived neurotrophic factor receptor [RE arranged during 
transfection (RET); refs. 1–3]. The inhibition of these RTKs blocks signal transduction, thereby affecting 
various cellular processes, such as tumor growth, tumor progression, angiogenesis, and metastasis (Fig. 1; 
ref. 4). 
 
 
 
Figure 1. Specific RTKs are blocked by sunitinib (chemical structure shown). Sunitinib is able to block different signaling 
pathways owing to its action on different RTKs such as PDGFRα and β, KIT, FLT3, RET, and VEGFRs 1, 2, and 3. Sunitinib 
inhibition of signaling pathways [phosphoinositide 3-kinase (PI3K)/AKT/mTOR, mitogen-activated protein kinase (MAPK), and 
PKC] triggers different antitumor effects (4). 
 
  
In a phase III study in treatment-naïve patients with metastatic renal cell carcinoma (RCC), sunitinib 
significantly doubled median progression-free survival compared with IFN-α and extended median 
overall survival beyond 2 years (5, 6). Sunitinib is approved for the first-line treatment of advanced or 
metastatic RCC and imatinib-resistant or imatinib-intolerant advanced gastrointestinal stromal tumors 
(GIST). 
 
Although sunitinib therapy is associated with several well-characterized side effects, the molecular 
mechanisms underlying these toxicities remain unclear, but they may be related to the additional effect of 
sunitinib on nonmalignant (normal) cells that also express sunitinib targets, or to the cross-talk between 
different intracellular signaling pathways. In this review, we examine the current knowledge about the 
molecular basis of sunitinib side effects, including asthenia, fatigue, hair depigmentation, cardiotoxicity, 
hypothyroidism, hypertension, dermatologic adverse events, and hematologic and gastrointestinal 
toxicities. 
Molecular Basis of Fatigue and Asthenia 
Fatigue and asthenia are among the most common symptoms experienced by cancer patients, 
comprising pathologic tiredness, muscle weakness, poor endurance, and impaired motor and cognitive 
function. Fatigue is one of the most commonly reported side effects of sunitinib treatment, although the 
degree of fatigue and its impact on quality of life is variable (7). In sunitinib phase III clinical trials, 34% 
to 62% of patients exhibited fatigue of any grade, with 5% to 15% reporting grade 3 to 4 fatigue. Asthenia 
was less common, with an all-grade frequency of 12% to 25% and grade 3 to 4 frequency of 3% to 11% 
(5, 6, 8, 9). 
 
The precise clinical mechanisms responsible for causing fatigue and asthenia are unknown but are 
likely to work through similar pathways. Cancer-related fatigue is known to involve both peripheral 
(originating in the muscles and related tissues) and central (developing in the CNS) mechanisms, and 
several possible pathophysiologic pathways have been explored (10). Looking at RCC specifically, a 
study in diabetic patients showed that sunitinib triggers a decrease in blood glucose levels (11), which 
may be involved in the induction of fatigue and/or asthenia. However, as both diabetic and nondiabetic 
patients treated with sunitinib experience fatigue and asthenia (11), other mechanisms may also be 
involved, as discussed below. 
AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is critical in ensuring a balance between anabolic and 
catabolic processes within the cell. As such, AMPK functions as an energy sensor protein that is activated 
in response to an increased cellular AMP-to-ATP ratio, occurring, for example, during nutrient starvation 
(pooled data in sunitinib-treated RCC show that grade 3–4 anorexia occurs in approximately 3% of 
patients; ref. 9) or vigorous muscular exercise. The serine-threonine kinase LKB1 is an important 
component of the AMPK pathway and modulates AMPK activity (12). Both the AMPK and LKB1 
kinases are potential targets for sunitinib (13), which may, therefore, impair the signaling pathway 
responsible for maintaining the correct energy cellular balance, resulting in fatigue and/or asthenia. 
Glucose transporters 
Glucose uptake occurs through facilitative diffusion in a process mediated by plasma membrane 
glucose transporters. Contractile activity in the muscles triggers glucose uptake in an insulin-independent 
manner. Nitric oxide synthase (NOS) is also stimulated in muscles in response to contractile activity, 
increasing nitric oxide (NO) production. Some research suggests that inhibition of NO production can 
block the ability of exercise to stimulate glucose transport (14). Other studies have shown that endothelial 
NOS is stimulated in a VEGFR-dependent manner (15).  
In light of these data, sunitinib-mediated inhibition of VEGFR may trigger inhibition of NOS and 
reduced production of NO, resulting in a reduction in glucose uptake. In addition, as VEGFR can convey 
its signal through protein kinase C (PKC), sunitinib may indirectly inhibit PKC activity. PKC mediates 
calcium-mediated glucose uptake in the muscle, and its inhibition could impair insulin-dependent glucose 
uptake to the muscle. 
Circadian rhythm disruption 
Ligands of growth factors may also play a role in circadian rhythm disruption, which can lead to 
symptom clusters, including fatigue, appetite loss, and sleep disruption (16). Animal studies have 
identified several ligands of interest, including TGF-α, prokinectin-2 (PK2; a molecule closely related to 
endocrine tissue VEGF), and cardiotropin-like cytokine (Clc; a molecule related to the proinflammatory 
cytokine interleukin 6). Although currently no clinical data support these associations in patients with 
RCC, clinical observations have linked elevated levels of TGF-α with fatigue, appetite loss, and flattened 
circadian rhythms in patients with metastatic colorectal cancer (17). 
Molecular Basis of Hair Depigmentation 
Hair depigmentation (gray coloration of scalp or facial hair) has been observed in approximately 10% 
of patients treated with sunitinib (18). Hair pigmentation is a result of melanin pigment produced by 
melanocytes being incorporated into keratinocytes of growing hair. Although the mechanisms causing 
depigmentation in response to sunitinib treatment are not fully understood, sunitinib does not affect the 
population of melanocytes associated with hair follicles (19), suggesting that the inhibitory effect of 
sunitinib takes place at the level of melanocyte function, rather than affecting development or survival. 
Signaling pathways during hair pigmentation 
Melanin biosynthesis is mediated by the transcriptional regulator microphthalmia-associated 
transcription factor (MITF), critical for melanocyte development and differentiation. MITF regulates the 
transcription of 3 major enzymes involved in melanin biosynthesis, tyrosinase (TYR), tyrosinase-related 
protein 1 (TYRP1), and tyrosinase-related protein 2 (DCT), as well as its action on other pigmentation 
factors. MITF is activated by phosphorylation, which is controlled principally by the SCF/KIT signaling 
pathway (20). Through the inhibition of KIT, sunitinib may prevent activation of MITF, resulting in a 
lack of enzymes responsible for melanin biosynthesis and, ultimately, impairing hair depigmentation. It is 
worth noting that hair depigmentation has not been reported with other TKIs, suggesting that kinases 
other than KIT may also be involved in the process. Alternatively, differences in the occurrence of 
depigmentation may reflect variations in tissue distribution patterns between the TKIs. 
Molecular Basis of Sunitinib Cardiotoxicity 
The reported incidence of cardiotoxicity (primarily left ventricular dysfunction) with sunitinib varies 
from approximately 11% to 16% in the phase III studies in patients with GIST or metastatic RCC, 
respectively (4, 7, 8). The molecular mechanisms that may explain sunitinib-induced cardiomyocyte 
cytotoxicity are reviewed below. 
  
Angiogenesis 
Among the targets of sunitinib, only PDGFRs are expressed by cardiomyocytes. Although the 
overexpression of PDGF can promote cardiomyocyte survival (21), endogenous expression of PDGF and 
its receptors does not seem to have the same effect. Therefore, it is likely that an off-target effect of 
sunitinib is responsible for the observed cardiotoxicity. 
 
Hypoxia is a critical component of myocardial ischemia. Hypoxia-inducible factor 1 (HIF-1) is a 
major regulator of the hypoxic response and plays an important role following ischemic infarction, in 
which supranormal amounts of HIF-1 may have a protective function (22). HIF-1 controls several 
signaling pathways critical for cellular response to hypoxia, leading to transcriptional activation of 
angiogenesis-related genes such as VEGF, PDGFB, angiopoietin-1 (ANGPT1), and angiopoietin-2 
(ANGPT2). Inhibition of VEGFR by sunitinib, with the ensuing antiangiogenic consequences, may 
therefore abolish the protective function of HIF-1 in myocardial ischemia, resulting in a potentially life-
threatening situation. In addition, TKI-mediated permanent inhibition of VEGF/VEGFR signaling may 
impair the normal angiogenic response, compromising the cardiomyocytes' response to pressure (23). 
 
Damage to cardiomyocytes following sunitinib-induced toxicity may also be a result of HIF-1–
mediated local adaptations to low oxygen tension, such as hypertension triggered by an inducible NOS-
related pathway (see below). 
Ribosomal protein S6 kinase and AMP-dependent kinase 
In an earlier review of possible molecular mechanisms of cardiotoxicity of TKIs, Force and colleagues 
(24) proposed that sunitinib cardiotoxicity might result from off-target inhibition of either AMPK or 
ribosomal protein S6 kinase (RSK1). Both kinases are predicted to be inhibited by sunitinib at clinically 
relevant concentrations (12). RSK1 promotes survival through the inhibitory phosphorylation of the 
proapoptotic factor BCL2-associated agonist of cell death (BAD), and AMPK may transduce prosurvival 
signals in the heart. Preclinical studies have since shown that sunitinib potently inhibited both AMPK and 
RSK1 at therapeutically relevant concentrations in vitro and caused dose-dependent damage to cultured 
myocytes (25). Sunitinib also inhibited phosphorylation of 2 isoforms of the AMPK target, acetyl-
coenzyme A carboxylase, in myocytes. However, sunitinib did not reduce cellular ATP levels in the 
myocytes, an effect that would be expected by cellular inhibition of AMPK, nor were the myocytes 
protected from sunitinib treatment by pretreatment with the AMPK-activating antidiabetic drug 
metformin (25). Although these results strongly suggest that AMPK inactivation is not responsible for 
sunitinib-induced cardiotoxicity, metformin generally activates AMPK indirectly. As such, involvement 
of AMPK, as well as effects on other kinases, cannot be ruled out. 
Impaired mitochondrial function 
Another theory to explain sunitinib cardiotoxicity is based on the observation that cardiac tissue uses 
high amounts of energy and is likely to be very sensitive to mitochondrial damage. Preclinical 
experiments have shown that sunitinib treatment of cultured cardiomyocytes leads to cytochrome c 
release into the cytosol (26), which can activate the mitochondrial pathway for cell apoptosis. Consistent 
with this finding, sunitinib treatment also activated caspase-9, which is an initiator caspase of the 
mitochondrial apoptotic pathway, and induced apoptosis of cardiomyocytes in vitro (26). Finally, 
mitochondrial damage was observed in human biopsies and in mice treated with sunitinib (26). However, 
studies in vitro using isolated rat heart mitochondria failed to find a direct effect of sunitinib on 
mitochondrial function at clinically relevant concentrations (27). These data do not preclude a secondary 
effect of sunitinib on mitochondria, which are sensitive to host stress and are often disrupted during 
necrosis or apoptosis, regardless of cause. Further studies are needed to elucidate the primary cause of 
sunitinib cardiotoxicity. 
  
Molecular Basis of Hypothyroidism 
Estimates of the incidence of hypothyroidism in patients treated with sunitinib vary widely. In phase 
III studies, reported rates have ranged from 4% to 16% (4, 7), and in a rare prospective observational 
study, 27% of patients treated with sunitinib developed sub- or clinical hypothyroidism requiring 
hormone replacement (28). The mechanisms by which sunitinib affects thyroid function remain unclear 
but may include antiangiogenic effects (29, 30), iodine uptake inhibition (31), destructive thyroiditis (32), 
inhibition of thyroid peroxidase activity (33), and reduction of vascularity (34) by capillary regression 
and/or constriction. 
 
The antiangiogenic effect of sunitinib may be responsible for capillary regression (29, 34) that 
enhances toxicity to the thyroid gland. In normal thyroid follicular cells, thyroid-stimulating hormone or 
thyrotropin (TSH) induces the expression of VEGF and VEGFR, thereby influencing angiogenesis (35). 
Sunitinib-associated thyroid toxicity may be caused by destruction of the normal thyroid follicular cells 
due to impaired blood flow and/or inhibition of VEGF signaling. 
 
The observation that iodine uptake is impaired in patients treated with sunitinib (31) prompted the 
theory that this effect mediates sunitinib-related hypothyroidism. However, preclinical studies found no 
effect of sunitinib on response of cultured thyroid cells to TSH and a dose-related increase in iodine 
uptake (36). 
 
Sunitinib is a highly effective inhibitor of the RET/PTC kinase, which plays a role in proliferative 
signaling pathways (37). Mutations in RET/PTC are thought to be key to the pathogenesis of a significant 
subset of papillary thyroid carcinomas (38), supporting the idea that the RET pathway plays a role in the 
normal physiology of the thyroid gland. Therefore, sunitinib-mediated RET/PTC inhibition may impair 
thyroid activity, inducing hypothyroidism. 
 
Although hypothyroidism is a well-known adverse effect of sunitinib, these abnormal findings in the 
thyroid gland may serve as potential biomarkers for tumor response to sunitinib (39) and may be related 
to progression-free survival of patients with metastatic RCC (40). 
Molecular Basis of Hypertension 
A considerable body of evidence suggests a link between hypertension and impaired angiogenesis. 
Hypertension, commonly associated with VEGF inhibitors, may be a biomarker of antitumor efficacy. 
Recently, hypertension associated with sunitinib treatment was shown to have a significant and 
independent association with improved clinical outcomes in metastatic RCC (41). Similar results have 
also been observed for axitinib (42). In hypertensive patients, features associated with angiogenesis 
include a reduced number of arterioles and capillaries, alterations in the microvascular network, decreased 
vascular wall flexibility, reduced NOS activity, and increased VEGF in plasma (43). Hypertension may 
result from depressed angiogenesis at the microcirculation level. A reduction of microvessel density and 
reduction of vascular areas leads to an increase in peripheral vascular resistance and hypertension. 
 
Sunitinib, as an antiangiogenic drug, may induce hypertension by exerting its influence on 
mechanisms controlled by nervous and hormonal factors that affect blood vessels. One of the most 
important factors is NO, an active vasodilator. VEGF enhances transcriptional activity of endothelial 
NOS (43), suggesting that VEGF could rapidly induce a hypotensive response. Conversely, VEGF-
signaling inhibition may partially block NO production in arteriole walls, triggering vascular systemic 
resistance and hypertension (44). 
  
Molecular Basis of Dermatologic Toxicity 
Sunitinib frequently causes dermatologic adverse events. In a pooled analysis of published literature 
(18), sunitinib-induced dermatologic reactions included hand–foot syndrome (19% of patients), skin rash 
(13%), skin xerosis (16%), dermatitis (8%), and yellow skin discoloration (28%; potentially a result of the 
orange excipient used in sunitinib tablets). Nails with asymptomatic subungual splinter hemorrhages 
(sometimes accompanied with periungual erythema) have also been reported (45). However, at present, 
data are lacking from studies undertaken to elucidate the underlying mechanisms causing these toxicities. 
Cell signaling and skin toxicity 
The deregulation of signaling pathways, a result of treatment with TKIs, can be used to explain the 
occurrence of dermatologic side effects and their toxicity. Several experiments have shown the presence 
of a paracrine feedback loop (46–48), established through VEGF, between keratinocytes and endothelial 
cells. Furthermore, stromal secretion of PDGF from cell-matrix fibroblasts may also be important in the 
biology of skin dermis (49). Therefore, the side effects of sunitinib on the skin may be inherent to its 
action on VEGF and PDGF signaling and to the inhibition of the epidermal growth factor receptor 
(EGFR) pathway through RAF kinase and/or VEGFR2 inhibition. 
 
Alternatively, VEGFR may be constitutively involved in the formation and repair of delicate spiral 
capillaries in the skin. The blockade of this receptor through sunitinib might override the physiologic 
restoration of these capillaries, triggering several side effects. For example, the failure to recover from 
damage in the capillaries of skin underneath nails may result in subungual splinter hemorrhages (45). In 
addition, skin toxicity of sunitinib may be a result of its action on the focal adhesion kinase (FAK)/paxilin 
pathway. As such, sunitinib may trigger changes in cell proliferation and focal adhesion turnover (50). 
Molecular Basis of Gastrointestinal Toxicity 
Diarrhea occurs frequently in patients treated with sunitinib, with an incidence in phase III studies 
ranging between 29% and 53% (4, 7). Other, less frequent, gastrointestinal adverse events include nausea, 
stomatitis, vomiting, mucosal inflammation, constipation, and dyspepsia, as well as flatulence and 
dysgeusia (4, 7, 8), often mild to moderate in severity. 
 
Very little is known about the mechanisms underlying sunitinib-related gastrointestinal toxicity. Other 
VEGFR inhibitors commonly lead to diarrhea, nausea, and vomiting, suggesting a class effect (51). 
However, it seems likely that the mechanisms underlying gastrointestinal toxicity with VEGFR inhibitors, 
such as sunitinib, seem distinct from those leading to gastrointestinal perforation associated with 
bevacizumab treatment (51). 
Molecular Mechanisms of Hematologic Toxicity 
Most patients with metastatic RCC receiving sunitinib treatment experience some form of 
hematologic toxicity (4, 5, 7). This toxicity may be induced by inhibition of the KIT receptor, expressed 
by hematopoietic progenitor cells (52). In biochemical and in vitro cell-based assays, sunitinib inhibited 
phosphorylation of the KIT receptor and cellular proliferation (2). In addition, sunitinib inhibits the 
autophosphorylation of PDGFR and FLT3 (the latter being also expressed primarily on hematopoietic 
stem cells; refs. 1, 2) and blocks signaling through their downstream effector, extracellular signal-
regulated kinase 1/2 (ERK1/2; ref. 2). Sunitinib-induced proliferative inhibition by blocking activated 
tyrosine kinases could result in myelosuppression. In fact, sunitinib treatment results in 
thrombocytopenia, probably because of myelosuppression. Thrombocytopenia may also be caused by 
hypertension (53) and by immune thrombocytopenic purpura induced by sunitinib treatment (54). 
However, it is unclear why some patients develop erythrocytosis, whereas others develop anemia. Other 
erythropoietic pathways may also be involved in the development of hematologic toxicities. 
Molecular Mechanisms of Rare Toxicities 
Sunitinib induces several rare toxicities, such as gastrointestinal perforation, colonic pneumatosis, 
rheumatoid arthritis, encephalopathy syndrome, chronic wounds, and hypophosphatemia. 
 
Perforation of the gastrointestinal wall and/or bleeding of the gastrointestinal mucosa are unique side 
effects of anti-VEGF therapies, but they are very rare events with VEGFR-directed TKIs (51). As 
sunitinib blocks VEGFR signaling, it may be responsible for colonic pneumatosis caused by deficiencies 
in the maintenance of the vessel network. 
 
Although the molecular causes of rheumatoid arthritis are unknown, autoimmunity may play a central 
role in its progression. The impact of VEGF inhibitors on the immune system has been shown by animal 
model studies in which VEGF inhibited the development of dendritic cells and increased B lymphocytes 
and immature myeloid cells (55). However, the effect of sunitinib on the immune system is controversial. 
A recent article showed that sunitinib impaired proliferation and function of human peripheral T cells and 
prevented T-cell–mediated immune response in mice (56), but an earlier publication suggested a lack of 
effect of sunitinib on primary immune responses (57). 
 
Posterior reversible encephalopathy syndrome (PRES) is characterized by clinical symptoms such as 
visual loss, including cortical blindness, headache, decreased alertness, and altered mental function. PRES 
probably results from disruption of cerebral vascular endothelial cells and damage of cerebrovascular 
autoregulation, leading to edema. Sunitinib may damage the capillary endothelium by targeting VEGFR 
and PDGFR. VEGF expression in the microvasculature adjacent to choroid plexus epithelium is required 
for the maintenance of the choroid plexus structure (58); inhibiting VEGF signaling may, therefore, result 
in loss of the choroid plexus structure. Moreover, in RCC patients with brain metastases, TKIs targeting 
the VEGFR seem to increase the incidence of fatal intracranial bleeding (59), probably because of 
destabilization of immature microvasculature. 
 
Patients with chronic wounds (secondary to diabetes, inflammation, or vascular insufficiency) may 
have altered healing capacity. PDGF and VEGF are essential for wound healing. Degranulation of 
platelets releases PDGF at the wound site, where its physiologic action is mediated via PDGFRA and 
PDGFRB. VEGF expression is upregulated in the skin after wounding through its direct action on both 
endothelial cells and keratinocytes. Treatment with the PDGFR inhibitor imatinib affects wound healing 
by reducing proliferation and the movement of fibroblasts and pericytes, inhibiting myofibroblast 
formation and diminishing type I collagen biosynthesis (60); we hypothesize that sunitinib may have a 
similar effect. 
 
Sunitinib induces an increase in the production of amylase and/or lipase by the exocrine pancreas (4, 
8), probably in response to necrosis or capillary regression, which in turn may be caused by the inhibition 
of VEGFR, Tie, and Eph receptors. Lower levels of blood glucose in diabetic patients treated with 
sunitinib (9) may be linked to a capillary regression in pancreatic islets and to IGF-I modulation by HIF-α 
or NF-κB activation, which induces decreased glucose uptake. 
 
Sunitinib-mediated blocking of ATP in active sites of RTKs may trigger the hypophosphatemia 
observed in patients treated with sunitinib. This blockade forces the cell to incorporate phosphate from 
other sources to restore the ATP levels. Serum phosphate alterations may also explain hypercalcemia, in 
which high calcium levels are coupled with low phosphate levels. 
  
Conclusions 
Targeted therapies represent a new pharmacologic strategy to fight against cancer. New drugs, such as 
TKIs, targeting specific molecules within important signaling pathways deregulated in cancer have shown 
notable success. 
 
Multitargeted agents commonly compete with ATP for binding to the ATP pocket of tyrosine kinase 
receptors, providing potential for the treatment of a broad range of tumors. However, the off-target and 
broad-spectrum activity associated with these multitargeted drugs confers them with a unique toxicity 
profile (61–63). At present, 6 targeted agents are approved for the treatment of metastatic RCC in Europe 
and/or the United States. Examination of the adverse-event profile associated with each of these agents 
shows some important similarities as well as differences (Table 1; refs. 6, 64–68). These differences may 
be partly attributable to the differences in RTK potencies when binding to various targets (Table 2; refs. 
69–71). 
Table 1. Selected all-grade adverse events associated with the targeted agents sunitinib, sorafenib, bevacizumab/IFN-α, 
temsirolimus, everolimus, and pazopanib, approved in Europe and/or the United States for the treatment of metastatic RCC 
Adverse event (%) Sunitinib Sorafenib 
Bevacizumab plus IFN-
α 
Temsirolimus Everolimus Pazopanib 
       
Anorexia 34 16 36 32 16 22 
Asthenia 20 — 32 51 18 14 
Diarrhea 61 43 20 27 17 52 
Dyspnea 10 14 13 28 8 — 
Fatigue 54 37 33 — 20 19 
Hand–foot syndrome 29 30 — — — — 
Hyperglycemia — — — 26 50 41 
Proteinuria — — 18 — — — 
Hypertension 20 17 26 — — 40 
Anemia 79 8 10 45 91 — 
Lymphopenia 68 — — — 42 31 
Neutropenia 77 — 7 7 11 34 
Thrombocytopenia 68 — 6 14 20 32 
Leucopenia 78 — — 6 26 32 
Discontinuations due to AEs 
(%) 
19 10 28 7 10 NR 
       
 
NOTE: Data from refs. 6, 64–68. 
Abbreviations: AE, adverse event; NR, not reported. 
 
  
Table 2. Potency of selected agents for various tyrosine kinase receptors 
IC50 (nM)
a 
Target Sunitinib Sorafenib Pazopanib Axitinib 
     
VEGFR-1 2 — 10 1.2 
VEGFR-2 10 90 30 0.25 
VEGFR-3 17 20 47 0.29 
PDGFR-β 8 57 84 1.7 
EGFR 880 58 — — 
c-KIT 10 68 74 1.6 
FGF-1R 880 580 14 230 
FLT-3 14 58 — — 
Raf-1 — 6 — — 
CSF-1R 100 — — — 
     
 
NOTE: Data from refs. 69–71. 
Abbreviations: FGF, fibroblast growth factor. 
↵aIC50 represents the concentration of a drug that is required to achieve 50% inhibition of the enzyme in a biochemical assay. 
For some toxicities, differentiating between the target and off-target effects of sunitinib is not 
straightforward. Comparing the toxicities associated with sunitinib with those associated with the 
selective anti-VEGF monoclonal antibody bevacizumab may be useful. For example, grade 3 to 4 left 
ventricular dysfunction has been observed to occur with greater frequency with sunitinib treatment than 
with either bevacizumab or sorafenib (0.3%, 1.4%, and 0.05% in phase I–III studies), suggesting a 
potential off-target effect (72). One potential explanation may be that the reduced left ventricular ejection 
fraction is a result of sunitinib-induced hypothyroidism (24). Another example is that dermatologic 
toxicities, specifically hand–foot skin reactions, occur much less commonly in patients treated with 
bevacizumab than in those treated with sunitinib. However, rather than hinting toward a potential off-
target effect of sunitinib, evidence suggests that dermatologic toxicities in patients treated with 
bevacizumab may be modulated by the presence of certain VEGF2 alleles (73). 
 
Currently no data from randomized clinical trials directly compare the activity and toxicity profile of 
various multitargeted agents. Two phase III studies comparing sunitinib with pazopanib 
(COMPARZ:NCT00720941) and axitinib with sorafenib, respectively, are ongoing; early results are 
expected by 2011 (74). Increased understanding of the pathogenesis of sunitinib-associated side effects 
may allow rational administration to patients. Optimizing sunitinib treatment is essential, as increased 
exposure is associated with improved clinical benefit (75). In a meta-analysis of data from patients with 
metastatic RCC and GIST, increased exposure was associated with longer time to progression, overall 
survival, higher probability of a response, and greater decrease in tumor size, but also with more adverse 
events, albeit of mild-to-moderate intensity in most patients (75). 
 
To date, only retrospective analyses about the association between occurrence of a defined adverse 
event and clinical outcome are available. In both axitinib and sunitinib studies, a relationship has been 
shown between incidence of hypertension and clinical outcome endpoints, including overall response rate 
and progression-free and overall survival (41, 42). 
 
Additionally, several retrospective studies have shown a relationship between the presence of 
hypothyroidism and improved antitumor efficacy in patients treated with sunitinib (34, 39, 40). Although 
further studies are required, the abnormalities in thyroid function or blood pressure following treatment 
with sunitinib may be potential biomarkers for tumor response to multitargeted agents.  
Understanding the molecular basis of sunitinib toxicity will help explain the mechanisms responsible 
for inducing undesirable side effects with the broader class of targeted agents, ultimately allowing the 
design of more effective targeted anticancer therapies with an improved safety profile. 
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